PD173074 Licensed by Pfizer

Catalog No.S1264

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Price Stock Quantity  
USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD173074 Chemical Structure

PD173074 Chemical Structure
Molecular Weight: 523.67

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

FGFR Inhibitors with Unique Features

  • Pan FGFR Inhibitor

    BGJ398 (NVP-BGJ398) FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.

  • Most Potent FGFR Inhibitor

    AZD4547 FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.

  • FDA-approved FGFR Inhibitor

    Ponatinib (AP24534) Approved by FDA for resistant or intolerant CML and Ph+ ALL.

  • Newest FGFR Inhibitor

    SSR128129E Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Product Information

  • Compare FGFR Inhibitors
    Compare FGFR Products
  • Research Area
  • Inhibition Profile
  • PD173074 Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
c-Src [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)

 View  More

IC50 ~25 nM 100 nM-200 nM 19.8 μM >50 μM
In vitro PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1581MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYi1T|dnUUN3ME2wMlAyOjJ3IN88US=>MULTRW5ITVJ?
KG-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzVc2xmUUN3ME2wMlA2OTJ7IN88US=>MVnTRW5ITVJ?
MFM-223M2fLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUK4[oxbUUN3ME2wMlIyPTd4IN88US=>M33Uc3NCVkeHUh?=
EoL-1-cellM3rSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXiXo1KSzVyPUCuN|I6QDRizszNM{DmTXNCVkeHUh?=
ECC10MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3MV4hLUUN3ME2wMlM{QDl6IN88US=>MmjBV2FPT0WU
H-EMC-SSM1TIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHVTWM2OD1yLkO0O|E2KM7:TR?=M2DUU3NCVkeHUh?=
AN3-CANX72WHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\hN2EzUUN3ME2wMlQxOTN|IN88US=>MXzTRW5ITVJ?
HuO-3N1M3rMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwNUS2OVMh|ryPMkXiV2FPT0WU
RT-112MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrSZpd5UUN3ME2wMlU1PzBzIN88US=>M2PRRnNCVkeHUh?=
NEC8MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVn6fHhrUUN3ME2wMlU3Ojh7IN88US=>NWDI[41jW0GQR1XS
D-263MGNFPrXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLwfodKSzVyPUCuO|EyPTlizszNM2O2SHNCVkeHUh?=
SW962MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwN{i5PFgh|ryPM1;FPXNCVkeHUh?=
BV-173MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnXcVZtUUN3ME2wMlg1PjJ|IN88US=>NVvQbJFIW0GQR1XS
MFE-280MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTKOoJlUUN3ME2wMlg2QDd{IN88US=>MX7TRW5ITVJ?
HuH-7MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlz6TWM2OD1zLkK0OFY1KM7:TR?=MVHTRW5ITVJ?
RS4-11NVHh[Yt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTFwM{O4PFYh|ryPMl3LV2FPT0WU
DMS-114MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{S0OWlEPTB;MT6zOlc{PyEQvF2=MUjTRW5ITVJ?
MSTO-211HNEDST5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XTNGlEPTB;MT60O|M4QCEQvF2=MVfTRW5ITVJ?
DU-145NUHJRVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTFwNUiyNVch|ryPNWq3dYlFW0GQR1XS
A172NEj4RY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTFwN{CzOVUh|ryPMWLTRW5ITVJ?
SBC-1MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfVTWM2OD1{LkC5OEDPxE1?MnXrV2FPT0WU
H9M1nmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1e0SWlEPTB;Mj6xOFMxPiEQvF2=M{\5UXNCVkeHUh?=
NCI-SNU-1M{\Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJwMUizPVQh|ryPNYXkbolNW0GQR1XS
NCI-H720MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmzTWM2OD1{LkKxNlg{KM7:TR?=MYfTRW5ITVJ?
HCC2218M1rNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkC1TWM2OD1{LkO3PVM6KM7:TR?=MlXjV2FPT0WU
G-401MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW[2TY1vUUN3ME2yMlQ4OTh7IN88US=>MXPTRW5ITVJ?
MPP-89MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXiTWM2OD1{LkS4N|Y1KM7:TR?=NXvxPZhCW0GQR1XS
697M17WO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTJwNkWzN|Eh|ryPMlXuV2FPT0WU
KARPAS-45NYK2WnE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoS1TWM2OD1{LkewO|Q4KM7:TR?=M4Lld3NCVkeHUh?=
MG-63NYH5emJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTJwOUSyOlIh|ryPM1\4OXNCVkeHUh?=
NTERA-S-cl-D1MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIK5fphKSzVyPUOuNFM1PzJizszNMmG1V2FPT0WU
G-402NYfHfHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\QXGlEPTB;Mz6xNlczPyEQvF2=MmLyV2FPT0WU
NKM-1Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTNwMUO1OlQh|ryPNX[3dm5FW0GQR1XS
RH-18NX3oSGJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4izNGlEPTB;Mz6xPVU6QCEQvF2=NUDGfYRFW0GQR1XS
NCI-H1092MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\rbJh5UUN3ME2zMlE6PjlizszNNFr4dnNUSU6JRWK=
RPMI-8226M3zaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rOWGlEPTB;Mz6yN|Q1PyEQvF2=NFPKbolUSU6JRWK=
GAMGNYDBcFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTNwNE[1O|Yh|ryPMn;aV2FPT0WU
HHMnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLxTWM2OD1|LkS3Olc3KM7:TR?=NXLq[GxtW0GQR1XS
RO82-W-1NUfJXFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\JTWM2OD1|LkS5PFU2KM7:TR?=MV3TRW5ITVJ?
CCRF-CEMMl2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrITWM2OD1|LkWwOFg5KM7:TR?=MnXuV2FPT0WU
NBsusSRM2LB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DZZWlEPTB;Mz62N|k3QSEQvF2=M2q0V3NCVkeHUh?=
CHL-1NHfUTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUOyXY5tUUN3ME2zMlY2Pzl7IN88US=>MXPTRW5ITVJ?
LK-2MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfZTWM2OD1|Lk[3NVM{KM7:TR?=NGXnbmtUSU6JRWK=
Hs-578-TNX;PNFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrNOYJxUUN3ME2zMlY4QDd|IN88US=>NW\Q[45OW0GQR1XS
CTB-1MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTMTWM2OD1|LkiwNFUyKM7:TR?=NGnCc|BUSU6JRWK=
ES5NX;YdY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofNTWM2OD1|LkizOlM4KM7:TR?=MXnTRW5ITVJ?
A204MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHVRnJFUUN3ME2zMlkzODd3IN88US=>Mn2yV2FPT0WU
SW780NFXpXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\RWVBKSzVyPUOuPVIzPDVizszNMmW5V2FPT0WU
EW-3NIGySY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fzOWlEPTB;Mz65PFkzOyEQvF2=NXXpVnMyW0GQR1XS
A704M2[zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmToTWM2OD12LkK4O|I{KM7:TR?=NUj0fYV5W0GQR1XS
LU-139MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHT2RlJKSzVyPUSuN|E2OzRizszNNEGxc4RUSU6JRWK=
CAL-72NUHuUm5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfibFBKUUN3ME20MlQyPzR4IN88US=>NXLLSWFDW0GQR1XS
D-336MGM2TkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3m1W2lEPTB;ND60OlgyPyEQvF2=MWnTRW5ITVJ?
LAMA-84MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\RR3ZpUUN3ME20MlU{OzFizszNMknkV2FPT0WU
GI-ME-NMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{D2UmlEPTB;ND61OFgyKM7:TR?=NFnER5dUSU6JRWK=
KM-H2MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPTTWM2OD12LkW1NlIzKM7:TR?=M2XEc3NCVkeHUh?=
NCI-H209NEC2SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLTTWM2OD12LkW4Nlg{KM7:TR?=MnrsV2FPT0WU
IGROV-1NHPLRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPJTWM2OD12Lki3NVY5KM7:TR?=NWWwVJRrW0GQR1XS
L-363NVrGdJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PWTWlEPTB;ND65OlY3PSEQvF2=MVTTRW5ITVJ?
SK-MEL-3Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rvTGlEPTB;NT6yOFA3KM7:TR?=MnLRV2FPT0WU
HuO9NHzWblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37Tb2lEPTB;NT6zPFg1OyEQvF2=MW\TRW5ITVJ?
NOS-1MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LGUmlEPTB;NT63NlkzPyEQvF2=MX7TRW5ITVJ?
NCI-H1770NUTYXFRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zkXGlEPTB;NT65OVA{OiEQvF2=NGe1b2FUSU6JRWK=
SF126MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTjXGJKSzVyPU[uNlE1ODZizszNMonKV2FPT0WU
ML-2M3j0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\STWM2OD14LkK0PVc4KM7:TR?=NF7qeHNUSU6JRWK=
CHP-134NIrCbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Ll[mlEPTB;Nj6yOVE5OiEQvF2=M1WwcXNCVkeHUh?=
NCI-H1355MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXNTWM2OD14LkSxO|M{KM7:TR?=M4GxdnNCVkeHUh?=
TE-12M{e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY[x[oNEUUN3ME22MlczPjdzIN88US=>MlvXV2FPT0WU
A4-FukMkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITQOZFKSzVyPU[uO|MyPDJizszNNVLJVoNtW0GQR1XS
MV-4-11M37F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHhcppKSzVyPU[uO|Y3OjZizszNM4fafHNCVkeHUh?=
SK-UT-1Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\uSYJYUUN3ME22MlkyPzh2IN88US=>M1fRd3NCVkeHUh?=
J-RT3-T3-5MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrvVpFKSzVyPUeuNFc4PjRizszNMYXTRW5ITVJ?
ME-180Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTdwMUC0NFQh|ryPNVm0PHRCW0GQR1XS
SK-MEL-28NGr5clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3qxb2lEPTB;Nz6zO|gyQSEQvF2=M4Hi[XNCVkeHUh?=
HAL-01MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfMZnlKSzVyPUeuOFg{PDFizszNNW\ESlNlW0GQR1XS
ES8M{DtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvzOIRKSzVyPUeuOlk3OjZizszNNH\ZPGFUSU6JRWK=
DBMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{WweGlEPTB;OD6xNVUxPCEQvF2=MWDTRW5ITVJ?
SK-NEP-1NHLI[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRThwNEixOFkh|ryPM3PZTHNCVkeHUh?=
COR-L88Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEm4doNKSzVyPUiuOVA6QDFizszNMnnJV2FPT0WU
LB1047-RCCNFXhW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWH3T3N{UUN3ME24MlUzOjF{IN88US=>MVrTRW5ITVJ?
NCI-H520M1TSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;BcWNKSzVyPUiuOlIyPTdizszNM{LuXHNCVkeHUh?=
SW954NGLOeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIn3NFRKSzVyPUiuOlk4QDZizszNNWn2ZolRW0GQR1XS
TE-6M{fVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPwTWM2OD16Lke1NVQ{KM7:TR?=NVP4eWxLW0GQR1XS
D-283MEDMoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvTVodyUUN3ME25MlA3PTN2IN88US=>NWnvfppFW0GQR1XS
DBTRG-05MGM3PkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2ftc2lEPTB;OT6wPVYxPyEQvF2=Mn;PV2FPT0WU
NCI-H446NGXPXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfCU2RKSzVyPUmuNlk2OjZizszNMnHsV2FPT0WU
HOSMkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTlwM{WxN|Qh|ryPMVTTRW5ITVJ?
ES4NH\LZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzEcnliUUN3ME25MlUxPTl3IN88US=>NWjme|ZSW0GQR1XS
EW-13M{TkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTTfno6UUN3ME25Mlg6ODV3IN88US=>MoHkV2FPT0WU
IST-MES1NILBPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[5PYdMUUN3ME25Mlk1PTN2IN88US=>NITLW2xUSU6JRWK=
CAS-1MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzjcmhKSzVyPUmuPVc3PTlizszNNHjKNYJUSU6JRWK=
EM-2NXTLZ2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrae2FKSzVyPUGwMlE{QTNizszNMlXUV2FPT0WU
SW948M3i2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDITWM2OD1zMD6xPFgzKM7:TR?=M1vZfHNCVkeHUh?=
OAW-42NHzyNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHyTWM2OD1zMD61NlY4KM7:TR?=NX7ldopUW0GQR1XS
BE-13MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\vTWM2OD1zMD62OVc3KM7:TR?=MnfjV2FPT0WU
KU812MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrw[G1KSzVyPUGwMlc{QTFizszNMUTTRW5ITVJ?
SK-MEL-30NWLmUXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYryTZhQUUN3ME2xNE45QTBzIN88US=>MVLTRW5ITVJ?
A2780NX;ROHlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{X6bGlEPTB;MUGuNFMxQCEQvF2=MljXV2FPT0WU
TGBC24TKBMk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zJfWlEPTB;MUGuNFc{PyEQvF2=NFHB[YFUSU6JRWK=
GOTOMle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnftTWM2OD1zMT6yNFg1KM7:TR?=NHnldIxUSU6JRWK=
NCI-H526M{XnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlW2TWM2OD1zMT6zPFM4KM7:TR?=NEn3XG9USU6JRWK=
BHT-101M3HpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfoTWM2OD1zMT60OFU3KM7:TR?=MV3TRW5ITVJ?
NCI-H1155NFjQNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEe4WoFKSzVyPUGxMlQ6PDdizszNM2S4NXNCVkeHUh?=
MCF7M1v0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFzLk[xOlch|ryPMWLTRW5ITVJ?
MKN45M13ROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFzLke5PVMh|ryPNVj4ZnJKW0GQR1XS
MOLT-16M3XmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPidJk1UUN3ME2xNU46Pjl{IN88US=>Ml62V2FPT0WU
YH-13M1ni[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPrS2I6UUN3ME2xNk4xOzR4IN88US=>MUPTRW5ITVJ?
P12-ICHIKAWANIXOUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrjdJVKSzVyPUGyMlM5PDVizszNM37vR3NCVkeHUh?=
GR-STMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjFU49KSzVyPUGyMlUzQTVizszNNUTZcpNiW0GQR1XS
CAKI-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLRTWM2OD1zMj63PVEh|ryPM3fYWnNCVkeHUh?=
LXF-289NHOwZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF|LkC4N|Uh|ryPMoX4V2FPT0WU
MHH-PREB-1MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmH6TWM2OD1zMz6yO|A1KM7:TR?=NHu0ZnBUSU6JRWK=
EW-16M4iz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfO[3luUUN3ME2xN{4{OTh5IN88US=>MWXTRW5ITVJ?
NCI-H82NHPKWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF|LkSxPVUh|ryPM{jF[3NCVkeHUh?=
MMAC-SFM1XVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL6TWM2OD1zMz60OVQ4KM7:TR?=NHjBVmxUSU6JRWK=
COLO-684NUnDZ|FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXMTWM2OD1zMz61N|E5KM7:TR?=MmO4V2FPT0WU
QIMR-WILNFqxSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr2SIVKSzVyPUGzMlgyODlizszNNIDrR4dUSU6JRWK=
NB69Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PIVmlEPTB;MUOuPVg3QCEQvF2=NHXYNWdUSU6JRWK=
NCI-H2291NIP4c2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX2U5FUUUN3ME2xOE41PDV|IN88US=>Mn:4V2FPT0WU
MKN7NWjnXnUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;VOGlEPTB;MUSuOlY4PiEQvF2=M4Sy[XNCVkeHUh?=
HDLM-2Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLGfGFKSzVyPUG1MlEzQDZizszNNWHvfJgzW0GQR1XS
A253NV[3WYhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHqfFJ4UUN3ME2xOU4{QDZ7IN88US=>MkDxV2FPT0WU
SK-LU-1NGqwNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTF3LkmwPVQh|ryPMo\FV2FPT0WU
MEG-01MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLiTWM2OD1zNT65NVA4KM7:TR?=NYLodm97W0GQR1XS
SK-N-DZNWi3R|N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S0bWlEPTB;MUWuPVM4PiEQvF2=M3n0dnNCVkeHUh?=
H4MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvKVIlKSzVyPUG2MlA5QCEQvF2=NY\nN4xMW0GQR1XS
LU-65M3\LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4f4[WlEPTB;MU[uN|M5PCEQvF2=MUHTRW5ITVJ?
NCI-H1048NInzPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2C2WGlEPTB;MU[uOVE3PSEQvF2=NHHBS5VUSU6JRWK=
LCLC-97TM1M3\R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7YSo9sUUN3ME2xOk42QDh7IN88US=>MnXxV2FPT0WU
CAL-120NH2wO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\uXlViUUN3ME2xOk46QDd7IN88US=>NGCzNW1USU6JRWK=
LU-134-ANIXuNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTF5LkOzPVEh|ryPNXPmXJFNW0GQR1XS
SK-MEL-1Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjKN2hKUUN3ME2xO{44OTJ5IN88US=>NYfSN4ZZW0GQR1XS
NCI-H69MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;3dGlEPTB;MUeuPVMxPyEQvF2=NIXDV5dUSU6JRWK=
MC116MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13oVmlEPTB;MUeuPVc2KM7:TR?=NIHBfYRUSU6JRWK=
UMC-11M1H1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;tNWlEPTB;MUiuNVc5QCEQvF2=NEnVUFRUSU6JRWK=
HCC1395MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXqSpBNUUN3ME2xPE41OzBzIN88US=>NULWZpR2W0GQR1XS
no-10MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXQTVhsUUN3ME2xPE43Ozh6IN88US=>NFnnRYlUSU6JRWK=
NYM1nLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF74XGRKSzVyPUG5MlA5ODlizszNMWHTRW5ITVJ?
OS-RC-2M3XsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHIOWVKSzVyPUG5MlEzPTJizszNNIrTWJpUSU6JRWK=
D-423MGNGHJOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn[3TWM2OD1zOT6zPVUzKM7:TR?=Mk[xV2FPT0WU
LC-2-adMmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLOTWM2OD1zOT63OlEzKM7:TR?=NXzC[ZZTW0GQR1XS
DU-4475NFXtS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHNTWM2OD1zOT64PFUzKM7:TR?=M{DWdnNCVkeHUh?=
YKG-1M1zBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnXTWM2OD1zOT65OlIh|ryPNHHqS|JUSU6JRWK=
HCC1569MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1G1SWlEPTB;MkCuNlYzPCEQvF2=M1v4OHNCVkeHUh?=
TYK-nuM4H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[1WWtKSzVyPUKwMlI5PDdizszNMXTTRW5ITVJ?
DELM4jPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jJU2lEPTB;MkCuPVgxQCEQvF2=MVPTRW5ITVJ?
MHH-ES-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlH5TWM2OD1{MT6zOVk4KM7:TR?=Mkj3V2FPT0WU
KARPAS-299NIKwXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTJzLkWyPUDPxE1?MUPTRW5ITVJ?
CTV-1MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVW5cnpbUUN3ME2yNU43OTd{IN88US=>NG\pUJVUSU6JRWK=
NCI-H2452MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG3WJpKSzVyPUKyMlY3PzdizszNMlzKV2FPT0WU
D-566MGMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3HTWM2OD1{Mj63OlAyKM7:TR?=MnvtV2FPT0WU
EFO-27M2W4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHFUo1KSzVyPUKzMlA3PTFizszNM4njb3NCVkeHUh?=
NCI-H596MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTJ|Lki1Nlch|ryPMWTTRW5ITVJ?
KS-1M1TyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJ2LkK3OVkh|ryPMYDTRW5ITVJ?
8305CNFPYXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnRPVBKSzVyPUK0MlQxPDVizszNNXz5[pc3W0GQR1XS
A427NW\SelNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHLS5VKSzVyPUK1MlA{OjNizszNMX;TRW5ITVJ?
COLO-800MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrD[XBlUUN3ME2yOU4yODZzIN88US=>NXvib4lzW0GQR1XS
SJRH30MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LkemlEPTB;MkWuN|kxQCEQvF2=MXrTRW5ITVJ?
MEL-HOM4fGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3T4UmlEPTB;MkWuOFMyQSEQvF2=NEezZnpUSU6JRWK=
FTC-133NXrCPZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LCb2lEPTB;MkWuPFE5PiEQvF2=MlPjV2FPT0WU
SF295MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjLSWcxUUN3ME2yOk4zQTZizszNNVnCUJppW0GQR1XS
SW1710MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJ4LkSxNlMh|ryPMV;TRW5ITVJ?
EFM-19MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJ4LkixOFUh|ryPM4H4S3NCVkeHUh?=
NB10NED2VnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXjcWpKSzVyPUK4MlIzQTdizszNMXvTRW5ITVJ?
TK10MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPXTWM2OD1{OD6yN|k6KM7:TR?=NVPUVWxzW0GQR1XS
D-502MGNYnQSoNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYO2ZYw2UUN3ME2yPE41KM7:TR?=NWnzcnVOW0GQR1XS
EW-18MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTJ6LkSzPFYh|ryPM2DTOHNCVkeHUh?=
VMRC-RCZNGm2cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XSdWlEPTB;MkiuPVQyKM7:TR?=NIHTdIlUSU6JRWK=
Ca9-22MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DyRWlEPTB;MkmuOFU2PyEQvF2=MonuV2FPT0WU
KYSE-70NHi3WGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ7LkW3PFYh|ryPNWSxR2diW0GQR1XS
A101DNWOwOW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnm1TWM2OD1{OT62OFczKM7:TR?=NHnZfGhUSU6JRWK=
WM-115M1Kxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJ7Lke2NFch|ryPNFfx[WhUSU6JRWK=
HCC2157MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPOTmhEUUN3ME2yPU45QDB5IN88US=>M3fEW3NCVkeHUh?=
TE-9NHHZTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLqTWM2OD1{OT64PFY2KM7:TR?=MXrTRW5ITVJ?
K-562MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnVbY5OUUN3ME2zNE4xQTN|IN88US=>MX\TRW5ITVJ?
SN12CMkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;rOmZFUUN3ME2zNE4yPDJ4IN88US=>MkToV2FPT0WU
ESS-1MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnFSFlKSzVyPUOwMlQ4PTlizszNMnX6V2FPT0WU
K5Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPhfmNKUUN3ME2zNE44PjRizszNNY\KWoc2W0GQR1XS
J82NXTobIhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPUT3hKSzVyPUOxMlA5QTdizszNMkDRV2FPT0WU
HOP-92MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV22eo1mUUN3ME2zNU4yOTFzIN88US=>MlPhV2FPT0WU
NCI-H2228Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLFTWM2OD1|MT6zNlk3KM7:TR?=Mn7FV2FPT0WU
OCI-AML2NE\1O4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTVTWM2OD1|MT6zOlEh|ryPMl3RV2FPT0WU
NCI-SNU-5MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTNzLkixN|ch|ryPMn\EV2FPT0WU
A3-KAWM3fEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLleWdjUUN3ME2zNU46OjR|IN88US=>NFjUUotUSU6JRWK=
LCLC-103HMnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jP[WlEPTB;M{KuNFE4OSEQvF2=MnLIV2FPT0WU
KY821NVf6PYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:ycIFOUUN3ME2zNk43QDh2IN88US=>NELNWGlUSU6JRWK=
JVM-2MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\yTWM2OD1|Mj65NFc6KM7:TR?=MXfTRW5ITVJ?
Mo-TNEnBSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjqW4lKSzVyPUOzMlExODVizszNM3ryb3NCVkeHUh?=
IA-LMMnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTN|LkK3OUDPxE1?MnPSV2FPT0WU
C8166Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXWeIRKSzVyPUOzMlMyQTJizszNNUXSWItPW0GQR1XS
TCCSUPMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17LWGlEPTB;M{OuOFMxPyEQvF2=M2DTNHNCVkeHUh?=
JEG-3NFnSbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEflUIlKSzVyPUOzMlQ4PjhizszNMWrTRW5ITVJ?
MS-1M1u1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml70TWM2OD1|Mz61OVUyKM7:TR?=NHzh[3BUSU6JRWK=
NCI-H1304MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjLNIlKSzVyPUOzMlU4OjVizszNM{jF[nNCVkeHUh?=
Ramos-2G6-4C10MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XtUWlEPTB;M{SuNFM{PSEQvF2=M2m1W3NCVkeHUh?=
MDA-MB-453NFTicVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXO5eVV{UUN3ME2zOE43Ozl3IN88US=>MmjjV2FPT0WU
KYSE-520MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vMcGlEPTB;M{SuO|E5OSEQvF2=MVrTRW5ITVJ?
SW900NIjDVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPuSpBKSzVyPUO0MlgyOTVizszNM2rkenNCVkeHUh?=
HCC2998MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[0dllKSzVyPUO1MlE2OjlizszNM{HZSHNCVkeHUh?=
A2058M4nHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fab2lEPTB;M{WuOlA3OSEQvF2=M4jjRXNCVkeHUh?=
OVCAR-3NIfLWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnsTWM2OD1|Nj6yNFQ2KM7:TR?=MlTJV2FPT0WU
MOLT-4NWX1TphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTN4LkKyPVQh|ryPMYLTRW5ITVJ?
CAPAN-1NGjiR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\WbWlEPTB;M{[uOFY6QSEQvF2=NWrkTFZGW0GQR1XS
SCC-9MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnv6TWM2OD1|Nz60NFI4KM7:TR?=MlPGV2FPT0WU
SF268NXTaSIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTN6LkO0N|Mh|ryPM3\lTnNCVkeHUh?=
HGC-27MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDqc4R7UUN3ME2zPE4{PzFzIN88US=>NHTQOI1USU6JRWK=
DOHH-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTN6LkexOVgh|ryPM1X6dXNCVkeHUh?=
KE-37NYXaNpczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnS2TWM2OD1|OD65PFI5KM7:TR?=NVjsd5YyW0GQR1XS
MOLT-13M3LFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTN7LkK1NFIh|ryPNET6d5hUSU6JRWK=
ES1NWLKRoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fFXWlEPTB;M{muN|g2KM7:TR?=NXvXS5J[W0GQR1XS
SK-OV-3MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTN7Lkm2OFMh|ryPNVvK[o1OW0GQR1XS
SNU-449NUTSRXg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jWOWlEPTB;NECuNFc3PCEQvF2=Moi5V2FPT0WU
KYSE-510NWnjVJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zETWlEPTB;NECuNVI6PSEQvF2=NHzTfIZUSU6JRWK=
HL-60MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTRyLkm3PFMh|ryPNHvaVXdUSU6JRWK=
DJM-1NVjEWJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPOTWM2OD12MD65O|k6KM7:TR?=NXXEZW5MW0GQR1XS
TGBC11TKBMnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnuR|l7UUN3ME20NU4xQTJ4IN88US=>NGTue3pUSU6JRWK=
U-2-OSMoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M371SWlEPTB;NEKuNlY1OSEQvF2=NXHCVGh5W0GQR1XS
NCI-H2030MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3xWJhQUUN3ME20Nk41OzZ6IN88US=>NWDZWnp{W0GQR1XS
LU-135M4PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj4NmdDUUN3ME20Nk42PDR5IN88US=>NGfwR25USU6JRWK=
ZR-75-30MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vsZWlEPTB;NEOuNFQ6OyEQvF2=NWX2U|FzW0GQR1XS
GT3TKBMorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\Z[Xc1UUN3ME20N{4zPjd7IN88US=>NWfXd4ZDW0GQR1XS
RPMI-2650NF\TSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;BWmlEPTB;NEOuO|gyPiEQvF2=NWDkeY5XW0GQR1XS
SASNVnhc4x1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPZTWM2OD12Mz65OVM1KM7:TR?=NYXSWJJGW0GQR1XS
MDA-MB-231NU\DSIVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfvTWM2OD12Mz65OlA6KM7:TR?=MknSV2FPT0WU
JVM-3NGLiN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2L2N2lEPTB;NESuNFU{OyEQvF2=NXzNW3BSW0GQR1XS
COLO-320-HSRNIrEb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTR2LkW2N|Mh|ryPMUnTRW5ITVJ?
SNB75Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXZR2JsUUN3ME20OE43OTB3IN88US=>NV[yTXBiW0GQR1XS
NCI-H441MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTR2LkmzNlgh|ryPNHrTT4JUSU6JRWK=
HCT-116NWnrdJRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzvRXZKSzVyPUS0Mlk5PjhizszNNGXxZ3RUSU6JRWK=
NCI-H226MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn4PYhKSzVyPUS1MlY{PjhizszNNHnteY5USU6JRWK=
CAL-33MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2S1bWlEPTB;NEWuPVIyPyEQvF2=MlnUV2FPT0WU
NCI-H1437NX\BPVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTqSod5UUN3ME20Ok4{OjFizszNNX\aPG1iW0GQR1XS
HCC1187NIrPdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTR4LkSyOVUh|ryPMoXvV2FPT0WU
NUGC-3NFv3R2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3KTWM2OD12Nj61O|A6KM7:TR?=NUS2Z2xNW0GQR1XS
T98GM3\MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTR5LkW0O{DPxE1?MljJV2FPT0WU
OVCAR-8NWPM[G5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTR5Lk[4N{DPxE1?NGCze3FUSU6JRWK=
LB2241-RCCNHHneVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[4bGJvUUN3ME20O{44OjdizszNM{HPcXNCVkeHUh?=
NCI-H358NIfycGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\UN2lEPTB;NEiuNVE2OiEQvF2=MXTTRW5ITVJ?
PANC-08-13NF;iV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\3fVdKSzVyPUS4MlE5PTNizszNM13x[XNCVkeHUh?=
KP-N-YNMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn6wTWM2OD12OD6yNVAzKM7:TR?=M33pPXNCVkeHUh?=
NCI-H1755MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPadmNKSzVyPUS4MlI4OjZizszNNYm1WJM2W0GQR1XS
NCI-N87NHqwOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jU[GlEPTB;NEiuNlk6OSEQvF2=MmHEV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro kinase inhibition assays Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.

Cell Assay: [4]

Cell lines KMS11 and KMS18
Concentrations Dissolved in DMSO, final concentrations ~100 nM
Incubation Time 48 hours
Method Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.

Animal Study: [1]

Animal Models Swiss Webster mice with induced corneal angiogenesis
Formulation Prepared in sterile fashion
Dosages ~2 mg/kg/day
Administration Administered intraperitoneally

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.

[2] Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527.

view more

Chemical Information

Download PD173074 SDF
Molecular Weight (MW) 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea

Frequently Asked Questions

  • Question 1
    What is the half-life of PD173074(S1264) in vivo?

    Answer: According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related FGFR Products

  • CH5183284 (Debio-1347)

    CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.

  • BLU9931

    BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • BGJ398 (NVP-BGJ398)

    BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.

  • AZD4547

    AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

    Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.

  • SSR128129E

    SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

  • LY2874455

    LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Recently Viewed Items

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us